Psychopharmacology

Guidance on psychotropic meds in pregnancy: personalize decisions, coordinate care, and plan early to prevent postpartum relapse.

GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.

Planning for prevention of perinatal psychiatric relapse with safer medication options.

Discover APA sessions on OCD therapies, gut-brain microbiome insights, AI, sports psychiatry, and geriatric updates from top clinicians.

Expert shares the use of liquid formulation ADHD medication and how to discuss with patients.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Lisdexamfetamine liquid targets ADHD and binge eating, easing pill-swallowing and sensory barriers to improve adherence.

Experts discuss rapid cycling and bipolar II, and weigh lithium as an often overlooked treatment option.

How antidepressant myths can raise suicide risk—and what evidence-based prescribing, tapering, and crisis supports really look like.

Joseph F. Goldberg, MD, urges evidence-based psychiatric deprescribing: continual med reviews, shared decisions, and smarter polypharmacy reduction.

Oral zervimesine blocks toxic amyloid and alpha-synuclein oligomers, as Cognition maps FDA strategy for Lewy body trials.

Leading psychiatric organizations respond to federal push for deprescribing.

CT-1812 shows promise in Lewy body dementia, stabilizing hallucinations and delusions while easing caregiver distress.

Learn how genetics shape psych med response and dosing.

New psychiatry drugs target dementia agitation, ADHD, depression, TRD, and schizophrenia—see which novel mechanisms may reach the FDA next.

HHS targets psychiatric overprescribing; expert Joseph F. Goldberg, MD, urges careful deprescribing—stop ineffective medications and replace with evidence-based treatments.

HHS targets “psychiatric overprescribing,” but experts urge thoughtful deprescribing—stopping ineffective medications while replacing them with evidence-based alternatives tailored to patients.

Learn how dual antipsychotics can mask the true cause of high prolactin, and how stepwise switches to aripiprazole or clozapine restore cycles.

Low soluble α2δ‑1 disrupts brain excitation‑inhibition balance in schizophrenia.

Learn when CBT/IPT beats medications, when to combine antidepressants, and why patient preference drives depression recovery in 6–12 weeks in this podcast.

New data shows stable symptoms when switching from atypical antipsychotics to Cobenfy using cross-titration.

FDA approves Axsome’s AXS-05 for Alzheimer’s agitation, backed by multiple trials.

Clinicians explore neuroscience-guided off-label prescribing.

Interim analysis suggests tazbentetol may regrow synapses, improving cognition and schizophrenia symptoms.